Development of 41Ca-Based pharmacokinetic model for the study of bone remodelling in humans

Manju Sharma, Zeljko Bajzer, Susanta K. Hui

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background and Objective: Initial studies show that 41Ca may be employed as a useful diagnostic bioassay for monitoring metabolic bone disease and its treatment management. The 41Ca-based pharmacokinetic model is developed to assess its feasibility in monitoring bone disease and clinical responsiveness to therapeutic regimens. Methods: A four-compartment calcium kinetic model is developed to interpret the results of clinically measured 41Ca tracer kinetics for oral and intravenous dose. This model is extended to simulate changes in bone turnover due to osteoporosis by using Gompertzian function with and without cellular accommodation. The rate constants obtained by fitting to the experimental data on drug intervention are used to simulate the impact of strategic treatment intervention. Results: The present model fits well with the available experimental data on 41Ca tracer kinetics. In the simulated osteoporotic model, the negative bone balance (i.e. bone loss) reflected by 41Ca/Ca urine ratio is used to demonstrate slow/fast increase over time compared to the normal state. The cellular accommodation impact is reflected by a recovery from perturbed balance. The model's predictive ability on the impact of therapeutic intervention is verified using published experimental data. The effect of bisphosphonate intervention results in positive bone balance (i.e. bone gain). Conclusion: The four-compartment 41Ca tracer kinetic model can be flexibly used in the interpretation of results obtained from ongoing clinical studies.

Original languageEnglish (US)
Pages (from-to)191-199
Number of pages9
JournalClinical Pharmacokinetics
Volume50
Issue number3
DOIs
StatePublished - 2011

Fingerprint

Bone Remodeling
Pharmacokinetics
Bone and Bones
Metabolic Bone Diseases
Bone Diseases
Diphosphonates
Biological Assay
Osteoporosis
Urine
Calcium
Therapeutics
Pharmaceutical Preparations

Keywords

  • Bone-resorption
  • Calcium
  • Osteoporosis
  • Pharmacokinetic- modelling
  • pharmacokinetics
  • Radionuclide-tests

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Development of 41Ca-Based pharmacokinetic model for the study of bone remodelling in humans. / Sharma, Manju; Bajzer, Zeljko; Hui, Susanta K.

In: Clinical Pharmacokinetics, Vol. 50, No. 3, 2011, p. 191-199.

Research output: Contribution to journalArticle

Sharma, Manju ; Bajzer, Zeljko ; Hui, Susanta K. / Development of 41Ca-Based pharmacokinetic model for the study of bone remodelling in humans. In: Clinical Pharmacokinetics. 2011 ; Vol. 50, No. 3. pp. 191-199.
@article{afcc0f715d2a4a71bb9c888d09777992,
title = "Development of 41Ca-Based pharmacokinetic model for the study of bone remodelling in humans",
abstract = "Background and Objective: Initial studies show that 41Ca may be employed as a useful diagnostic bioassay for monitoring metabolic bone disease and its treatment management. The 41Ca-based pharmacokinetic model is developed to assess its feasibility in monitoring bone disease and clinical responsiveness to therapeutic regimens. Methods: A four-compartment calcium kinetic model is developed to interpret the results of clinically measured 41Ca tracer kinetics for oral and intravenous dose. This model is extended to simulate changes in bone turnover due to osteoporosis by using Gompertzian function with and without cellular accommodation. The rate constants obtained by fitting to the experimental data on drug intervention are used to simulate the impact of strategic treatment intervention. Results: The present model fits well with the available experimental data on 41Ca tracer kinetics. In the simulated osteoporotic model, the negative bone balance (i.e. bone loss) reflected by 41Ca/Ca urine ratio is used to demonstrate slow/fast increase over time compared to the normal state. The cellular accommodation impact is reflected by a recovery from perturbed balance. The model's predictive ability on the impact of therapeutic intervention is verified using published experimental data. The effect of bisphosphonate intervention results in positive bone balance (i.e. bone gain). Conclusion: The four-compartment 41Ca tracer kinetic model can be flexibly used in the interpretation of results obtained from ongoing clinical studies.",
keywords = "Bone-resorption, Calcium, Osteoporosis, Pharmacokinetic- modelling, pharmacokinetics, Radionuclide-tests",
author = "Manju Sharma and Zeljko Bajzer and Hui, {Susanta K.}",
year = "2011",
doi = "10.2165/11537840-000000000-00000",
language = "English (US)",
volume = "50",
pages = "191--199",
journal = "Clinical Pharmacokinetics",
issn = "0312-5963",
publisher = "Adis International Ltd",
number = "3",

}

TY - JOUR

T1 - Development of 41Ca-Based pharmacokinetic model for the study of bone remodelling in humans

AU - Sharma, Manju

AU - Bajzer, Zeljko

AU - Hui, Susanta K.

PY - 2011

Y1 - 2011

N2 - Background and Objective: Initial studies show that 41Ca may be employed as a useful diagnostic bioassay for monitoring metabolic bone disease and its treatment management. The 41Ca-based pharmacokinetic model is developed to assess its feasibility in monitoring bone disease and clinical responsiveness to therapeutic regimens. Methods: A four-compartment calcium kinetic model is developed to interpret the results of clinically measured 41Ca tracer kinetics for oral and intravenous dose. This model is extended to simulate changes in bone turnover due to osteoporosis by using Gompertzian function with and without cellular accommodation. The rate constants obtained by fitting to the experimental data on drug intervention are used to simulate the impact of strategic treatment intervention. Results: The present model fits well with the available experimental data on 41Ca tracer kinetics. In the simulated osteoporotic model, the negative bone balance (i.e. bone loss) reflected by 41Ca/Ca urine ratio is used to demonstrate slow/fast increase over time compared to the normal state. The cellular accommodation impact is reflected by a recovery from perturbed balance. The model's predictive ability on the impact of therapeutic intervention is verified using published experimental data. The effect of bisphosphonate intervention results in positive bone balance (i.e. bone gain). Conclusion: The four-compartment 41Ca tracer kinetic model can be flexibly used in the interpretation of results obtained from ongoing clinical studies.

AB - Background and Objective: Initial studies show that 41Ca may be employed as a useful diagnostic bioassay for monitoring metabolic bone disease and its treatment management. The 41Ca-based pharmacokinetic model is developed to assess its feasibility in monitoring bone disease and clinical responsiveness to therapeutic regimens. Methods: A four-compartment calcium kinetic model is developed to interpret the results of clinically measured 41Ca tracer kinetics for oral and intravenous dose. This model is extended to simulate changes in bone turnover due to osteoporosis by using Gompertzian function with and without cellular accommodation. The rate constants obtained by fitting to the experimental data on drug intervention are used to simulate the impact of strategic treatment intervention. Results: The present model fits well with the available experimental data on 41Ca tracer kinetics. In the simulated osteoporotic model, the negative bone balance (i.e. bone loss) reflected by 41Ca/Ca urine ratio is used to demonstrate slow/fast increase over time compared to the normal state. The cellular accommodation impact is reflected by a recovery from perturbed balance. The model's predictive ability on the impact of therapeutic intervention is verified using published experimental data. The effect of bisphosphonate intervention results in positive bone balance (i.e. bone gain). Conclusion: The four-compartment 41Ca tracer kinetic model can be flexibly used in the interpretation of results obtained from ongoing clinical studies.

KW - Bone-resorption

KW - Calcium

KW - Osteoporosis

KW - Pharmacokinetic- modelling

KW - pharmacokinetics

KW - Radionuclide-tests

UR - http://www.scopus.com/inward/record.url?scp=79551693061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551693061&partnerID=8YFLogxK

U2 - 10.2165/11537840-000000000-00000

DO - 10.2165/11537840-000000000-00000

M3 - Article

C2 - 21294596

AN - SCOPUS:79551693061

VL - 50

SP - 191

EP - 199

JO - Clinical Pharmacokinetics

JF - Clinical Pharmacokinetics

SN - 0312-5963

IS - 3

ER -